Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
By Eric Topor
A hospital group isn’t giving up its court fight with the HHS over cuts to a Medicare drug discount program that took effect Jan. 1.
A lawsuit filed by the American Hospital Association seeking to block a Medicare rule implementing an almost 30 percent cut to reimbursements for drugs obtained under the 340B program was dismissed Dec. 29 for lack of proper standing. But AHA General Counsel Melinda Hatton told Bloomberg Law Jan. 2 that "[t]here are a number of avenues for pursuing our legal challenge to the court’s decision and we expect to announce shortly which route or routes we intend to take.”
The AHA could appeal the ruling or refile the lawsuit based on actual Medicare claims affected by the 340B program cut in an effort to address the standing issue the U.S. District Court for the District of Columbia cited in its dismissal order. A legislative effort is also underway to rescind the program cut in the form of a proposed House bill ( H.R. 4392) introduced Nov. 14, though its prospects for passage aren’t known.
Mark D. Polston, a partner at King & Spalding in Washington, told Bloomberg Law Jan. 2 that an appeal of the dismissal would be “difficult” because the plaintiffs, which also include the Association of American Medical Colleges and America’s Essential Hospitals, would need “to convince the court of appeals to address the case on an expedited basis” and show that the trial court’s ruling was incorrect.
In the meantime, hospitals that depend on the 340B program to help fund hospital operations face an uncertain cost-benefit analysis going forward, according to Justin C. Linder, a health-care attorney with Dughi, Hewit & Domalewski PC in Cranford, N.J. Linder told Bloomberg Law Jan. 2 that hospitals are struggling not only with uncertainty over the 340B reimbursement cuts—and whether litigation or legislation will reverse them—but also with implementing a set of modifiers announced Dec. 13 that hospitals participating in the 340B program must use starting Jan. 1.
“It’s not an easy fix” to incorporate the modifiers into hospital billing systems, Linder said. There’s a cost associated with compliance with the modifier requirement and discerning which drugs purchased through the 340B program were prescribed to which patients, and this cost, combined with reduced reimbursements, could lead some hospitals to decide to drop out of the program, Linder said. Drugs obtained through the 340B program are administered by physicians on an outpatient basis through Medicare Part B.Hospitals that are unable to implement the modifiers and continue to bill Medicare for drugs acquired through the 340B program could be required to return those reimbursements as overpayments within 60 days, Linder said. Failure to do so, he cautioned, could transform a known overpayment into a false claim, exposing a hospital to triple damages and per claim fines under the False Claims Act. Linder suggested that hospitals struggling with implementing the modifiers follow the Centers for Medicare & Medicaid Services’ suggestion in the Dec. 13 modifier announcement to coordinate with their designated Medicare administrative contractor (MAC). The CMS said in the announcement that a hospital encountering difficulty implementing the modifiers into its billing system “should contact its MAC to discuss whether holding claims or rebilling claims may be an option.”
Linder didn’t believe that other hospitals would file their own parallel litigation against the Department of Health and Human Services over the reimbursement cuts. Instead, he predicted that hospitals would leave the legal and congressional lobbying efforts to reverse the 340B rule and the reimbursement cut to their respective industry groups, though Linder said members of Congress would be hearing from hospitals in their districts on the issue.
Polston said the AHA could ask the court to halt the rate cut as a preliminary matter if it refiles its lawsuit, irrespective of whether the lawsuit is ultimately successful or any retroactive payments are later issued. Linder said a refiled lawsuit should “move fairly quickly,” which could bring some needed certainty to hospitals dependent on the 340B program.
To contact the reporter on this story: Eric Topor in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Peyton Sturges at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)